These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 15476222)

  • 1. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M; Graninger WB; Steiner G; Smolen JS
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
    Aringer M; Steiner G; Graninger WB; Höfler E; Steiner CW; Smolen JS
    Arthritis Rheum; 2007 Jan; 56(1):274-9. PubMed ID: 17195231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of infliximab in active SLE: a pilot study.
    Uppal SS; Hayat SJ; Raghupathy R
    Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open study of B lymphocyte depletion in systemic lupus erythematosus.
    Leandro MJ; Edwards JC; Cambridge G; Ehrenstein MR; Isenberg DA
    Arthritis Rheum; 2002 Oct; 46(10):2673-7. PubMed ID: 12384926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica.
    Karppinen J; Korhonen T; Malmivaara A; Paimela L; Kyllönen E; Lindgren KA; Rantanen P; Tervonen O; Niinimäki J; Seitsalo S; Hurri H
    Spine (Phila Pa 1976); 2003 Apr; 28(8):750-3; discussion 753-4. PubMed ID: 12698115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients.
    Matsumura R; Umemiya K; Sugiyama T; Sueishi M; Umibe T; Ichikawa K; Yoshimura M;
    Clin Exp Rheumatol; 2009; 27(3):416-21. PubMed ID: 19604433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
    Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
    Elkayam O; Burke M; Vardinon N; Zakut V; Yitzhak RB; Paran D; Levartovsky D; Litinsky I; Caspi D
    Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic blockade of TNF in patients with SLE-promising or crazy?
    Aringer M; Smolen JS
    Autoimmun Rev; 2012 Mar; 11(5):321-5. PubMed ID: 21619949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.
    Gottenberg JE; Merle-Vincent F; Bentaberry F; Allanore Y; Berenbaum F; Fautrel B; Combe B; Durbach A; Sibilia J; Dougados M; Mariette X
    Arthritis Rheum; 2003 Jul; 48(7):2019-24. PubMed ID: 12847696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus.
    Hayat SJ; Uppal SS
    Mod Rheumatol; 2007; 17(2):174-7. PubMed ID: 17437178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG; Jones RB; Burns SM; Jayne DR
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.